Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?

Simply Wall St.07-06

Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising questions about what the pipeline could ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649643971?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-07-06 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649643971","market":"hk","top_or_hot":-1,"title":"Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?","media":"Simply Wall St.","content":"<div>\n<p>Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising questions about what the pipeline could ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-06 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising questions about what the pipeline could ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the","article_id":"2649643971","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649643971","pubTimestamp":1783304690,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising questions about what the pipeline could mean for the stock.\nSee our latest analysis for Nektar Therapeutics.\nNektar Therapeutics’ recent 10.3% 1 day share price return to US$71.04 and 23.9% 1 month share price return suggest momentum has picked up again, alongside index inclusions and fresh enthusiasm around its autoimmune pipeline,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NKTR":"内克塔治疗"},"translate_title":"Nektar Therapeutics(NKTR)推进自身免疫产品线，上涨空间是否已被消化？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":1.5},"content_text":"Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising questions about what the pipeline could mean for the stock. See our latest analysis for Nektar Therapeutics. Nektar Therapeutics’ recent 10.3% 1 day share price return to US$71.04 and 23.9% 1 month share price return suggest momentum has picked up again, alongside index inclusions and fresh enthusiasm around its autoimmune pipeline, despite a 3 month share price decline of 4.9% and a very large 3 year total shareholder return of more than 7x. If the recent move in Nektar Therapeutics has you looking beyond a single stock, this is a good moment to see what else is moving across 40 healthcare AI stocks. With Nektar Therapeutics now in multiple Russell indices, a recent share price around US$71, a very large multi year return and a sizeable discount to analyst targets, investors have to ask: is there still an opportunity here, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 53.6% Undervalued Compared with Nektar Therapeutics' last close at $71.04, the most widely followed narrative applies a fair value of $153.25, creating a wide valuation gap that hinges largely on expectations for rezpegaldesleukin and the broader autoimmune pipeline.  Strong initial Phase IIb and ongoing data for REZPEG in atopic dermatitis, combined with a large and growing addressable market (expected to reach nearly $30B by 2033), position Nektar to access significant new revenue streams and improve long-term earnings as the population ages and chronic inflammatory diseases rise globally.  Read the complete narrative. Curious what kind of revenue path, margin shift and future earnings multiple are being used to support that valuation gap? The narrative leans on aggressive revenue expansion, a sharp turn in profitability and a premium future earnings multiple that is far above typical sector benchmarks. Result: Fair Value of $153.25 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this undervalued case for Nektar Therapeutics still leans heavily on REZPEG clearing late stage hurdles, as well as on the company managing ongoing losses and funding needs. Find out about the key risks to this Nektar Therapeutics narrative. Another View on Nektar Therapeutics: What P/S Says While the fair value narrative for Nektar Therapeutics points to a large upside gap, the current P/S ratio of 43.1x tells a very different story. It is well above the US Pharmaceuticals industry average of 6.7x, above the peer average of 12x, and above the fair ratio of 17.7x that our model suggests the market could move toward over time. In practice, that means a lot of future success already appears built into the price on this metric. Any shortfall in execution or timelines could matter more than usual, while outperformance could keep the premium intact longer than skeptics expect. See what the numbers say about this price — find out in our valuation breakdown. NasdaqCM:NKTR P/S Ratio as at Jul 2026Next Steps With sentiment around Nektar Therapeutics clearly split between concern and optimism, take a moment to review the data for yourself and move quickly to shape your own view by weighing its 1 key reward and 3 important warning signs. Looking for more investment ideas beyond Nektar Therapeutics? If Nektar Therapeutics has caught your attention, do not stop at a single stock. Use the tools available, compare ideas and keep your watchlist working for you.  Target potential mispricings across the market by reviewing companies flagged in the 44 high quality undervalued stocks. Strengthen your downside protection by focusing on companies highlighted in the 74 resilient stocks with low risk scores. Spot earlier stage opportunities with strong financial quality by scanning the screener containing 18 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nektar Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649643971","isCrawlerRequest":true}